Related Experiment Videos
When to switch and what to switch to: strategic use of antiretroviral therapy
1Cornell Clinical Trials Unit, Weill Medical College of Cornell University, New York, USA.
Abstract:
Clinical cohort studies suggest that as many as 60% of patients experience virologic failure of a first-line antiretroviral regimen. Second-line and rescue (or salvage) regimens have a poorer success record: Most studies presented to date show a short-term virologic response rate of only approximately 30% in treatment-experienced individuals. That rate will improve with better understanding of what causes initial virologic failure, continued development of new antiretroviral agents (including drugs with new mechanisms of action) and new treatment strategies (including dual-protease inhibitor regimens), and more widespread use of resistance testing. Further clinical research is needed to improve salvage options, and physicians should consider enrolling treatment-experienced patients in clinical trials.
Insights
Many patients fail initial HIV treatment, with salvage regimens showing only 30% success. Improved understanding of treatment failure and new drugs are crucial for better outcomes in experienced individuals.
Area of Science:
- Infectious Diseases
- Virology
- Clinical Pharmacology
Background:
- First-line antiretroviral therapy (ART) failure affects up to 60% of patients.
- Treatment-experienced individuals often have poor outcomes with second-line and salvage regimens, with short-term virologic response rates around 30%.
Purpose of the Study:
- To review the challenges and potential improvements in antiretroviral therapy for treatment-experienced patients.
- To highlight the need for enhanced strategies to manage virologic failure.
Main Methods:
- Review of clinical cohort studies and existing literature on antiretroviral treatment outcomes.
- Analysis of factors contributing to virologic failure in first-line and subsequent treatment regimens.
Main Results:
- High rates of virologic failure observed in both initial and salvage ART regimens.
- Limited short-term efficacy of current second-line and salvage regimens in treatment-experienced populations.
Conclusions:
- Improving salvage options requires a deeper understanding of virologic failure mechanisms.
- Development of novel antiretroviral agents with new mechanisms of action and advanced treatment strategies, including resistance testing, is essential.
- Clinical trials are vital for advancing treatment efficacy in patients with complex treatment histories.